EMBL Ventures Closes $55M Fund | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – EMBL ventures, the venture capital arm of the European Molecular Biology Laboratory, today announced the €40 million ($55 million) first close of its EMBL Technology Fund II.

The venture arm of Heidelberg, Germany-based EMBL will remain focused on investments in European biotech and medtech companies and said that it intends to commit between €2 million and €5 million per investment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.

The San Diego Union-Tribune takes a look at the work to be done in personalized medicine.

An op-ed in the Wall Street Journal calls for the establishment of a patent court staffed by judges and experts with science backgrounds.

In PLOS this week: variants that affect COPD biomarkers, high genetic diversity of Cryptococcus gattii in Brazil, and more.